ArticleMetabolic brain disease2025
Gut microbiota and serum metabolomics unveil the role of Phellinus ribis polysaccharides in improving Alzheimer's disease symptoms in senescence-accelerated mice.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The complex of gut microbial metabolites and sex hormones in Alzheimer's disease.Seminars in immunopathology · 2026Review
- Ultrasound-assisted extraction optimization of Fructus Tribuli polysaccharides: How stir-frying processing alters structures and enhances antihypertensive efficacy.Ultrasonics sonochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), a complex neurodegenerative disorder with limited therapeutic options, urgently requires innovative strategies targeting its underlying mechanisms. Phellinus ribis polysaccharides (PRG), a bioactive compound with proven neuroprotective and microbiota-modulating effects, hold promise for addressing AD pathology through gut-brain axis regulation. This study aims to investigate the effects of PRG on the gut microbiota composition and serum metabolomic profile of a senescence-accelerated mouse model (SAMP8) and to reveal its potential mechanisms in alleviating symptoms of AD. The gut microbiota composition of SAMP8 mice treated with PRG was analyzed using 16S rRNA gene sequencing. Non-targeted metabolomics, based on ultra-performance liquid chromatography quadrupole/electrostatic field orbitrap high-resolution mass spectrometry, was employed to analyze changes in metabolites in the serum samples. Spearman correlation analysis was further used to explore the association between gut microbiota and serum metabolites. PRG significantly improved gut dysbiosis in SAMP8 mice by increasing the abundance of beneficial bacterial genera, reducing pathogenic bacteria levels, and restoring the dominance of advantageous bacterial phyla. Serum metabolomics analysis revealed that PRG intervention led to significant changes in AD-related metabolites, including phenylalanine and oxidative stress markers. Combined analysis indicated a correlation between changes in gut microbiota and serum metabolites. PRG can alleviate AD symptoms in senescence-accelerated mice by regulating gut microbiota and serum metabolites, providing scientific evidence for PRG as a potential therapeutic agent for AD. This study explores the role of gut microbiota and serum metabolites under PRG intervention in neurodegenerative diseases.
Indexed as
Identifiers
40445406What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.